Sarafloxacin HCl (Synonyms: A-56620)

Sarafloxacin (hydrochloride) (A-56620 (hydrochloride)) is a quinolone antibiotic drug.

Sarafloxacin (hydrochloride) is a fluoroquinolone antibiotic registered for use against poultry diseases. Sarafloxacin treatment demonstrated mineralization to 14CO2 amounting to 0.58%, 0.49%, and 0.57% in loam, silt loam, and sandy loam soils, respectively, at the termination of the test[1]. The inhibitory level of sarafloxacin for the tested bacteria was strain dependent. It appeared that in broth culture Escherichia coli isolates were sensitive to sarafloxacin concentrations 5-fold lower than the concentrations present in the simulated gut model, suggesting that sarafloxacin may be partially unavailable due to absorption to organic matter in the model[2].

Administering Sarafloxacin (hydrochloride) in the feed for 5 d at a dose of 10 or 12.5 mg/kg of fish proved efficacious in treating channel catfish infected with E. ictaluri in all three field trials. Average survival of the nonmedicated group was 43% in trial 1, 11°% in trial 2, and 59% in trial 3. Survival of the corresponding Sarafloxacin hydrochloride-medicated groups averaged 68, 48, and 73%. Antibiotic therapy with Sarafloxacin hydrochloride significantly (P < 0.05) improved survival in all trials[3].

References:
[1]. Marengo, J.R., et al., Aerobic biodegradation of (14C)-sarafloxacin hydrochloride in soil. Environmental Toxicology and Chemistry, 1997. 16(3): p. 462-471.
[2]. McConville, M.L., et al., Effects of sarafloxacin hydrochloride on human enteric bacteria under simulated human gut conditions. Vet Q, 1995. 17(1): p. 1-5.
[3]. Johnson, M.R., K.L. Smith, and C.R. Boyle, Field efficacy trials of the antibacterial sarafloxacin-hydrochloride (A-56620) for treatment of Edwardsiella ictaluri infections in channel catfish. Journal of aquatic animal health, 1992. 4(4): p. 244-251.